mesalamine and tofacitinib

mesalamine has been researched along with tofacitinib in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Awasthi, BP; Chaudhary, P; Jeong, BS; Karmacharya, U; Kim, JA; Kim, YE; Lee, IH; Nam, TG; Regmi, SC1
Day, AS; Eliadou, E; Gearry, RB; Inns, SJ; Rowbotham, DS; Schultz, M; Thompson-Fawcett, MW; Walmsley, R1
Siegmund, B; Sonnenberg, E1
Bosdelekidou, EE; Economopoulos, KP; Iliopoulou, SM; Kokkinidis, DG; Kousoulis, AA; Tassos, AG; Texakalidis, PT1
Battat, R; Dulai, PS; Feagan, BG; Jairath, V; Ma, C; Parker, CE; Sandborn, WJ1
Huang, E; Patel, S; Rubin, DT; Shaffer, SR1

Reviews

2 review(s) available for mesalamine and tofacitinib

ArticleYear
Emerging treatments for ulcerative colitis: a systematic review.
    Scandinavian journal of gastroenterology, 2017, Volume: 52, Issue:9

    Topics: Andrographis paniculata; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Colitis, Ulcerative; Gastrointestinal Agents; Humans; Induction Chemotherapy; Mesalamine; Piperidines; Plant Extracts; Pyrimidines; Pyrroles; Remission Induction

2017
Innovations in Oral Therapies for Inflammatory Bowel Disease.
    Drugs, 2019, Volume: 79, Issue:12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Discovery; Heterocyclic Compounds, 3-Ring; Humans; Indans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Mesalamine; Oxadiazoles; Phosphodiesterase Inhibitors; Piperidines; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Lysosphingolipid; Triazoles

2019

Other Studies

4 other study(ies) available for mesalamine and tofacitinib

ArticleYear
Synthesis and activity of N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)acetamide analogues as anticolitis agents via dual inhibition of TNF-α- and IL-6-induced cell adhesions.
    Bioorganic & medicinal chemistry letters, 2021, 07-01, Volume: 43

    Topics: Acetamides; Animals; Cell Adhesion; Colitis; Dose-Response Relationship, Drug; Interleukin-6; Molecular Structure; Rats; Structure-Activity Relationship; Trinitrobenzenesulfonic Acid; Tumor Necrosis Factor-alpha

2021
New Zealand Society of Gastroenterology Guidelines for the Management of Refractory Ulcerative Colitis.
    The New Zealand medical journal, 2015, Oct-16, Volume: 128, Issue:1423

    Topics: Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Appendectomy; Azathioprine; Colitis, Ulcerative; Cyclosporine; Drug Resistance; Drug Therapy, Combination; Fecal Microbiota Transplantation; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Infliximab; Leukapheresis; Mercaptopurine; Mesalamine; Methotrexate; New Zealand; Pediatrics; Piperidines; Proctocolectomy, Restorative; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recurrence; Severity of Illness Index; Tacrolimus; Tumor Necrosis Factor-alpha

2015
Ulcerative Colitis.
    Digestion, 2016, Volume: 94, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Biosimilar Pharmaceuticals; Colitis, Ulcerative; Gastrointestinal Agents; Glucocorticoids; Humans; Immunosuppressive Agents; Infliximab; Integrins; Janus Kinases; Mercaptopurine; Mesalamine; Piperidines; Pyrimidines; Pyrroles; Remission Induction; Tumor Necrosis Factor-alpha

2016
Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis.
    The American journal of gastroenterology, 2021, 01-01, Volume: 116, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Biological Products; Colitis, Ulcerative; Cost-Benefit Analysis; Deprescriptions; Drug Therapy, Combination; Gastrointestinal Agents; Humans; Infliximab; Markov Chains; Mesalamine; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years

2021